R&D News | pharmaphorum

News

Biogen, Ionis trumpet Alzheimer's data, but shares dip

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

News

AstraZeneca adds another Chinese asset, from Dizal

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

News

First trial of Bundibugyo Ebola vaccine starts in UK

Oxford University has launched what it says is the world's first phase I trial of a vaccine specifically designed to protect against Bundibugyo Ebola.

News